Lakefront Biotherapeutics (LKFT) Cash from Financing Activities (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 12 years of Cash from Financing Activities data on file, last reported at -$597080.3 in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$597080.3, up 43.85% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.2 million (up 37.14% YoY), and the FY2025 annual result was -$3.8 million, up 27.59% from the prior year.
• Cash from Financing Activities fell to -$597080.3 in Q1 2026 per LKFT's latest filing, from -$471437.6 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at -$28058.4 in Q1 2022 and troughed at -$2.0 million in Q4 2022.
• A 5-year average of -$1.0 million and a median of -$1.1 million in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities slumped 626.82% in 2023, then surged 72.5% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at -$2.0 million in 2022, then surged by 34.55% to -$1.3 million in 2023, then slumped by 33.76% to -$1.7 million in 2024, then surged by 72.5% to -$471437.6 in 2025, then decreased by 26.65% to -$597080.3 in 2026.
• Business Quant data shows LKFT's Cash from Financing Activities at -$597080.3 in Q1 2026, -$471437.6 in Q4 2025, and -$1.5 million in Q3 2025.